Investigative Sites Recognize Company’s Leadership in Advancing Clinical Research Through Collaborative Site Relationships
RALEIGH, N.C. – October 15, 2018 – Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it was awarded the Society for Clinical Research Sites (SCRS) Eagle Award in the CRO category for the second consecutive year. Presented during the annual SCRS Site Solutions Summit, the award recognizes the CRO that best exemplifies a site-focused approach to clinical trial management, demonstrating outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships.
“Receiving this site-selected award again this year recognizes the strength of our relationships with sites around the globe,” said Clare Grace, PhD, Vice President, Site and Patient Access, Syneos Health who accepted the award on behalf of Syneos Health at the Summit. “We continue to see the value that our collaborative site approach unlocks, including providing insights that allow for faster start up and efficient trial delivery. I would like to thank the dedicated employees at Syneos Health, and the investigative sites we work with, for their dedication to redefining how we speed the development of important therapies to patients.”
"Congratulations to Syneos Health for winning the 2018 CRO Eagle Award for the second year in a row," said SCRS president Christine Pierre. "The site community continues to recognize the Company’s outstanding leadership, professionalism and partnership. SCRS looks forward to our continued partnership with Syneos Health to support the site community."
This year’s winners were selected by investigative sites – nearly 10,000 research sites in 47 countries – who voted for the CRO they believe best demonstrates a strong commitment to site partnership. Selection criteria included availability of qualified staff to support sites, willingness to collaborate, protocol design and execution, financial consideration and partnering with sites for future work.
At the SCRS Site Solutions Summit, Syneos Health further demonstrated its continued commitment to sites and advancing research through thought leader panel conversations on topics including site payments, tele-medicine and remote visits and leveraging technology to drive patient recruitment. The Company also served on the Site Patient Recruitment Innovation Award (SPRIA) judging panel and hosted its annual Site Appreciation Reception to recognize and celebrate the vital role sites play in the clinical trial process.
To learn more about Syneos Heath’s site and patient engagement programs, including the Company’s Catalyst Site Program that supports faster start up and efficient delivery of studies for biopharmaceutical customers in Early Phase, Oncology, Psychiatry, Vaccine and Ophthalmology, please visit https://www.syneoshealth.com/site-relationships-and-catalyst-program.
About Syneos Health
Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 23,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are Shortening the distance from lab to life® visit syneoshealth.com.
Investor Relations Contact:
Senior Vice President, Investor Relations
+1 919 745 2745
Executive Director, External Communications
+1 202 210 5992